Skip to main content

Table 2 The reporting number and percentage for each item of the CONSORT checklist of the included 70 studies

From: The quality of reporting of randomized controlled trials of electroacupuncture for stroke

Section/Topic Item No Checklist item n % (n /70) 95%CI
 Title and abstract 1a Identification as a randomized trial in the title 12 17 [9 to 28]
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 54 77 [66 to 86]
 Introduction
  Background and objectives 2a Scientific background and explanation of rationale 63 90 [80 to 96]
2b Specific objectives or hypotheses 65 93 [84 to 98]
 Methods
  Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 58 83 [72 to 91]
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 0 0 [0 to 5]
  Participants 4a Eligibility criteria for participants 70 100 [95 to 100]
4b Settings and locations where the data were collected 58 83 [72 to 91]
  Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were actually administered 70 100 [95 to 100]
  Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 68 97 [90 to 100]
6b Any changes to trial outcomes after the trial commenced, with reasons 1 1 [0 to 8]
  Sample size 7a How sample size was determined 4 6 [2 to 14]
7b When applicable, explanation of any interim analyses and stopping guidelines 7 10 [4 to 20]
  Randomisation      
  Sequence generation 8a Method used to generate the random allocation sequence 26 37 [26 to 50]
8b Type of randomization; details of any restriction (such as blocking and block size) 20 29 [18 to 41]
  Allocation concealment mechanism 9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned 10 14 [7 to 25]
  Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions 7 10 [4 to 20]
  Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how 11 16 [8 to 27]
11b If relevant, description of the similarity of interventions 6 9 [3 to 18]
  Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 68 97 [90 to 100]
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 0 0 [0 to 5]
 Results
  Participant flow (a diagram is strongly recommended) 13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome 5 7 [2 to 16]
13b For each group, losses and exclusions after randomization, together with reasons 15 21 [13 to 33]
  Recruitment 14a Dates defining the periods of recruitment and follow-up 44 63 [50 to 74]
14b Why the trial ended or was stopped 2 3 [0 to 10]
  Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 23 33 [22 to 45]
  Baseline data 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 57 81 [70 to 90]
  Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) 2 3 [0 to 10]
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 0 0 [0 to 5]
  Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory 1 1 [0 to 8]
  Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 21 30 [20 to 42]
 Discussion
  Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 10 14 [7 to 25]
21 Generalisability (external validity, applicability) of the trial findings 13 19 [10 to 30]
  Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 22 31 [21 to 44]
 Other information
  Registration 23 Registration number and name of trial registry 0 0 [0 to 5]
  Protocol 24 Where the full trial protocol can be accessed, if available 1 1 [0 to 8]
  Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 14 20 [11 to 31]
  Total mean scorea    13.0 ± 4.0  
  1. aMean ± SD